Paper II — 2022 May (Supplementary) (2010 Scheme) — Q6
2 min read
Paper II
2022 May (Supplementary) (2010 Scheme)
Question
Metoclopramide
Q63 marksShort Notes
Answer
Metoclopramide is a D2 receptor antagonist with an additional prokinetic action.
MOA: metoclopramide → blocks D2 receptors at the chemoreceptor trigger zone → antiemetic effect; also acts as a 5-HT4 agonist and D2 antagonist within the GI tract itself → increases gastric emptying and lower esophageal sphincter tone (genuine prokinetic action, distinct from its pure antiemetic effect).
Uses: nausea and vomiting (including chemotherapy-induced and postoperative), gastroparesis, GERD-related symptoms, as an aid to radiological GI procedures (accelerates gastric emptying).
Adverse effects: extrapyramidal symptoms (dystonia, akathisia — since it crosses the blood-brain barrier and blocks central D2 receptors, unlike domperidone), hyperprolactinemia/galactorrhea, drowsiness, diarrhea.